{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:44:48Z","timestamp":1792467888096,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40272-026-00759-0","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:24:18Z","timestamp":1783351458000},"page":"343-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in the Pharmacological Management of Pediatric Spondyloarthritis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-8273","authenticated-orcid":false,"given":"Umit","family":"Gul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-5308","authenticated-orcid":false,"given":"Elif Kilic","family":"Konte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-4909","authenticated-orcid":false,"given":"Mehmet","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-7720","authenticated-orcid":false,"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"759_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5152\/eurjrheum.2021.20235","volume":"9","author":"M Y\u0131ld\u0131z","year":"2022","unstructured":"Y\u0131ld\u0131z M, Ha\u015flak F, Adrovi\u00e7 A, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6. Juvenile spondyloartropathies. EJR. 2022;9:42\u20139. https:\/\/doi.org\/10.5152\/eurjrheum.2021.20235.","journal-title":"EJR"},{"key":"759_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"759_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093166","volume":"14","author":"C Laz\u0103r","year":"2025","unstructured":"Laz\u0103r C, Cri\u0219an M, Man O-I, Sur LM, Sama\u0219ca G, Bolundu\u021b AC. Juvenile spondyloarthropathies: diagnostic and therapeutic advances\u2014a narrative review. JCM. 2025;14:3166. https:\/\/doi.org\/10.3390\/jcm14093166.","journal-title":"JCM"},{"key":"759_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1297-x","volume":"19","author":"S Gmuca","year":"2017","unstructured":"Gmuca S, Xiao R, Brandon TG, Pagnini I, Wright TB, Beukelman T, et al. Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther. 2017;19:84. https:\/\/doi.org\/10.1186\/s13075-017-1297-x.","journal-title":"Arthritis Res Ther"},{"key":"759_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard.2007.072512","volume":"67","author":"LS Gensler","year":"2008","unstructured":"Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis. 2008;67:233\u20137. https:\/\/doi.org\/10.1136\/ard.2007.072512.","journal-title":"Ann Rheum Dis"},{"key":"759_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17:257\u201369. https:\/\/doi.org\/10.1038\/s41584-021-00590-6.","journal-title":"Nat Rev Rheumatol"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/acr.22665","volume":"68","author":"PF Weiss","year":"2016","unstructured":"Weiss PF, Xiao R, Biko DM, Chauvin NA. Assessment of sacroiliitis at diagnosis of juvenile spondyloarthritis by radiography, magnetic resonance imaging, and clinical examination. Arthritis Care Res (Hoboken). 2016;68:187\u201394. https:\/\/doi.org\/10.1002\/acr.22665.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10067-022-06080-8","volume":"41","author":"U Kaya Akca","year":"2022","unstructured":"Kaya Akca U, Batu ED, Sener S, Balik Z, Kasap Cuceoglu M, Atalay E, et al. The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clin Rheumatol. 2022;41:1785\u201392. https:\/\/doi.org\/10.1007\/s10067-022-06080-8.","journal-title":"Clin Rheumatol"},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00296-017-3837-8","volume":"37","author":"A Adrovic","year":"2017","unstructured":"Adrovic A, Sezen M, Barut K, Sahin S, Acikel C, Demirkaya E, et al. The performance of classification criteria for juvenile spondyloarthropathies. Rheumatol Int. 2017;37:2013\u20138. https:\/\/doi.org\/10.1007\/s00296-017-3837-8.","journal-title":"Rheumatol Int"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/acr.25491","volume":"77","author":"PF Weiss","year":"2025","unstructured":"Weiss PF, Brandon TG, Aggarwal A, Burgos-Vargas R, Colbert RA, Horneff G, et al. Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis\/Spondylitis-related juvenile idiopathic arthritis criteria capture youth with axial spondyloarthritis? Arthritis Care Res. 2025;77:785\u201391. https:\/\/doi.org\/10.1002\/acr.25491.","journal-title":"Arthritis Care Res"},{"key":"759_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus. J Rheumatol. 2019;46:190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","journal-title":"J Rheumatol"},{"key":"759_CR12","first-page":"1900","volume":"30","author":"A Martini","year":"2003","unstructured":"Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30:1900\u20133.","journal-title":"J Rheumatol"},{"key":"759_CR13","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1002\/art.22173","volume":"54","author":"ML Stoll","year":"2006","unstructured":"Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564\u201372. https:\/\/doi.org\/10.1002\/art.22173.","journal-title":"Arthritis Rheum"},{"key":"759_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/art.42959","volume":"76","author":"PF Weiss","year":"2024","unstructured":"Weiss PF, Brandon TG, Aggarwal A, Burgos\u2010Vargas R, Colbert RA, Horneff G, et al. Classification criteria for axial disease in youth with juvenile spondyloarthritis. Arthritis Rheumatol. 2024;76:1797\u2013808. https:\/\/doi.org\/10.1002\/art.42959.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR15","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/acr.25014","volume":"75","author":"PF Weiss","year":"2023","unstructured":"Weiss PF, Brandon TG, Lambert RG, Biko DM, Chauvin NA, Francavilla ML, et al. Data-driven magnetic resonance imaging definitions for active and structural sacroiliac joint lesions in juvenile spondyloarthritis typical of axial disease: a cross-sectional international study. Arthritis Care Res (Hoboken). 2023;75:1220\u20137. https:\/\/doi.org\/10.1002\/acr.25014.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.rdc.2021.07.001","volume":"47","author":"H Srinivasalu","year":"2021","unstructured":"Srinivasalu H, Sikora KA, Colbert RA. Recent updates in juvenile spondyloarthritis. Rheumatic Dis Clin North Am. 2021;47:565\u201383. https:\/\/doi.org\/10.1016\/j.rdc.2021.07.001.","journal-title":"Rheumatic Dis Clin North Am"},{"key":"759_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12969-023-00878-9","volume":"21","author":"SOO Peltoniemi","year":"2023","unstructured":"Peltoniemi SOO, Glerup M, Lahdenne P, Eklund KK, Aalto K. Disease characteristics of HLA-B27 positive and negative finnish patients with juvenile idiopathic arthritis\u2014results of the 18-year cohort follow-up study. Pediatr Rheumatol Online J. 2023;21:94. https:\/\/doi.org\/10.1186\/s12969-023-00878-9.","journal-title":"Pediatr Rheumatol Online J"},{"key":"759_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0238-9","volume":"16","author":"M Goirand","year":"2018","unstructured":"Goirand M, Breton S, Chevallier F, Duong N-P, Uettwiller F, Melki I, et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis \/ juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol Online J. 2018;16:21. https:\/\/doi.org\/10.1186\/s12969-018-0238-9.","journal-title":"Pediatr Rheumatol Online J"},{"key":"759_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000366","volume":"3","author":"A Wei\u00df","year":"2017","unstructured":"Wei\u00df A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD Open. 2017;3:e000366. https:\/\/doi.org\/10.1136\/rmdopen-2016-000366.","journal-title":"RMD Open"},{"key":"759_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.13020","volume":"190","author":"C Vitulano","year":"2017","unstructured":"Vitulano C, Tedeschi V, Paladini F, Sorrentino R, Fiorillo MT. The interplay between HLA-B27 and ERAP1\/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis. Clin Exp Immunol. 2017;190:281\u201390. https:\/\/doi.org\/10.1111\/cei.13020.","journal-title":"Clin Exp Immunol"},{"key":"759_CR21","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.24763","volume":"60","author":"ML DeLay","year":"2009","unstructured":"DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633\u201343. https:\/\/doi.org\/10.1002\/art.24763.","journal-title":"Arthritis Rheum"},{"key":"759_CR22","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.1073\/pnas.1011736107","volume":"107","author":"JC Goodall","year":"2010","unstructured":"Goodall JC, Wu C, Zhang Y, McNeill L, Ellis L, Saudek V, et al. Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A. 2010;107:17698\u2013703. https:\/\/doi.org\/10.1073\/pnas.1011736107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"759_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069\u201376. https:\/\/doi.org\/10.1038\/nm.2817.","journal-title":"Nat Med"},{"key":"759_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461\u20133. https:\/\/doi.org\/10.1126\/science.1135245.","journal-title":"Science"},{"key":"759_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","volume":"294","author":"C Bridgewood","year":"2020","unstructured":"Bridgewood C, Sharif K, Sherlock J, Watad A, McGonagle D. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev. 2020;294:27\u201347. https:\/\/doi.org\/10.1111\/imr.12840.","journal-title":"Immunol Rev"},{"key":"759_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71:258\u201370. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR27","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373:2534\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med"},{"key":"759_CR28","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC-C, Sieper J, J\u00e4rvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295\u2013302. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213328.","journal-title":"Ann Rheum Dis"},{"key":"759_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2019;78:1015\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213654.","journal-title":"Ann Rheum Dis"},{"key":"759_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra0905980","volume":"363","author":"TA Manolio","year":"2010","unstructured":"Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166\u201376. https:\/\/doi.org\/10.1056\/NEJMra0905980.","journal-title":"N Engl J Med"},{"key":"759_CR31","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(11)60071-8.","journal-title":"Lancet"},{"key":"759_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329\u201337. https:\/\/doi.org\/10.1038\/ng.2007.17.","journal-title":"Nat Genet"},{"key":"759_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001195","volume":"6","author":"P Danoy","year":"2010","unstructured":"Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, Pointon J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn\u2019s disease. PLoS Genet. 2010;6:e1001195. https:\/\/doi.org\/10.1371\/journal.pgen.1001195.","journal-title":"PLoS Genet"},{"key":"759_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730\u20138. https:\/\/doi.org\/10.1038\/ng.2667.","journal-title":"Nat Genet"},{"key":"759_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","volume":"16","author":"C Pitzalis","year":"2020","unstructured":"Pitzalis C, Choy EHS, Buch MH. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat Rev Rheumatol. 2020;16:590\u20139. https:\/\/doi.org\/10.1038\/s41584-020-0491-4.","journal-title":"Nat Rev Rheumatol"},{"key":"759_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1510-6","volume":"20","author":"ML Stoll","year":"2018","unstructured":"Stoll ML, Weiss PF, Weiss JE, Nigrovic PA, Edelheit BS, Bridges SL, et al. Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther. 2018;20:14. https:\/\/doi.org\/10.1186\/s13075-018-1510-6.","journal-title":"Arthritis Res Ther"},{"key":"759_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/art.42289","volume":"75","author":"M Berland","year":"2023","unstructured":"Berland M, Meslier V, Berreira Ibraim S, Le Chatelier E, Pons N, Maziers N, et al. Both disease activity and HLA\u2013B27 status are associated with gut microbiome dysbiosis in spondyloarthritis patients. Arthritis Rheumatol. 2023;75:41\u201352. https:\/\/doi.org\/10.1002\/art.42289.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR38","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1002\/art.22181","volume":"54","author":"B Flat\u00f8","year":"2006","unstructured":"Flat\u00f8 B, Hoffmann-Vold A-M, Reiff A, F\u00f8rre \u00d8, Lien G, Vinje O. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum. 2006;54:3573\u201382. https:\/\/doi.org\/10.1002\/art.22181.","journal-title":"Arthritis Rheum"},{"key":"759_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.pcl.2018.03.006","volume":"65","author":"PF Weiss","year":"2018","unstructured":"Weiss PF, Colbert RA. Juvenile spondyloarthritis: a distinct form of juvenile arthritis. Pediatr Clin North Am. 2018;65:675\u201390. https:\/\/doi.org\/10.1016\/j.pcl.2018.03.006.","journal-title":"Pediatr Clin North Am"},{"key":"759_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40272-020-00416-0","volume":"22","author":"JM Bridges","year":"2020","unstructured":"Bridges JM, Stoll ML. Treatment of juvenile spondyloarthritis: where we stand. Pediatr Drugs. 2020;22:603\u201315. https:\/\/doi.org\/10.1007\/s40272-020-00416-0.","journal-title":"Pediatr Drugs"},{"key":"759_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles\u2010Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non\u2010systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71:846\u201363. https:\/\/doi.org\/10.1002\/art.40884.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00792-0","volume":"21","author":"Y Guo","year":"2023","unstructured":"Guo Y, Fang Y, Zhang T, Pan Y, Wang P, Fan Z, et al. Axial involvement in enthesitis-related arthritis: results from a single-center cohort. Pediatr Rheumatol Online J. 2023;21:13. https:\/\/doi.org\/10.1186\/s12969-023-00792-0.","journal-title":"Pediatr Rheumatol Online J"},{"key":"759_CR43","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/1756-185X.14845","volume":"26","author":"P Wu","year":"2023","unstructured":"Wu P, Huang C, Liao P-F, Ruperto N, Zeng H. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis. Int J Rheum Dis. 2023;26:2119\u201321. https:\/\/doi.org\/10.1111\/1756-185X.14845.","journal-title":"Int J Rheum Dis"},{"key":"759_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/acr.24963","volume":"75","author":"I Foeldvari","year":"2023","unstructured":"Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2023;75:975\u201382. https:\/\/doi.org\/10.1002\/acr.24963.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41584-024-01079-8","volume":"20","author":"S Shenoi","year":"2024","unstructured":"Shenoi S, Horneff G, Aggarwal A, Ravelli A. Treatment of non-systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2024;20:170\u201381. https:\/\/doi.org\/10.1038\/s41584-024-01079-8.","journal-title":"Nat Rev Rheumatol"},{"key":"759_CR46","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/14656566.2020.1796970","volume":"21","author":"A Marino","year":"2020","unstructured":"Marino A, De Souza M, Giani T, Cimaz R. Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies. Expert Opin Pharmacother. 2020;21:2161\u20138. https:\/\/doi.org\/10.1080\/14656566.2020.1796970.","journal-title":"Expert Opin Pharmacother"},{"key":"759_CR47","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<3C808::AID-ART6>3E3.0.CO;2-T","volume":"41","author":"MA van Rossum","year":"1998","unstructured":"van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41:808\u201316. https:\/\/doi.org\/10.1002\/1529-0131(199805)41:5%3c3C808::AID-ART6%3e3E3.0.CO;2-T.","journal-title":"Arthritis Rheum"},{"key":"759_CR48","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/ard.61.10.941","volume":"61","author":"R Burgos-Vargas","year":"2002","unstructured":"Burgos-Vargas R, V\u00e1zquez-Mellado J, Pacheco-Tena C, Hern\u00e1ndez-Gardu\u00f1o A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941\u20132. https:\/\/doi.org\/10.1136\/ard.61.10.941.","journal-title":"Ann Rheum Dis"},{"key":"759_CR49","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2017.07.014","volume":"16","author":"R Cimaz","year":"2017","unstructured":"Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev. 2017;16:1008\u201315. https:\/\/doi.org\/10.1016\/j.autrev.2017.07.014.","journal-title":"Autoimmun Rev"},{"key":"759_CR50","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"key":"759_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5152\/TurkArchPediatr.2024.23221","volume":"59","author":"E Nur Sunar Yayla","year":"2024","unstructured":"Nur Sunar Yayla E, Y\u0131ld\u0131z \u00c7, Esmeray \u015eenol P, Kara\u00e7ay\u0131r N, Gezgin Y\u0131ld\u0131r\u0131m D, Bakkalo\u011flu SA. How safe are biological agents in pediatric rheumatology? Turk Arch Pediatr. 2024;59:185\u201392. https:\/\/doi.org\/10.5152\/TurkArchPediatr.2024.23221.","journal-title":"Turk Arch Pediatr"},{"key":"759_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3899\/jrheum.170251","volume":"45","author":"PF Weiss","year":"2018","unstructured":"Weiss PF, Xiao R, Brandon TG, Pagnini I, Wright TB, Beukelman T, et al. Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: the first year after diagnosis. J Rheumatol. 2018;45:107\u201314. https:\/\/doi.org\/10.3899\/jrheum.170251.","journal-title":"J Rheumatol"},{"key":"759_CR53","first-page":"935","volume":"34","author":"I Olivieri","year":"2016","unstructured":"Olivieri I, Fanizza C, Gilio M, Ravasio R. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol. 2016;34:935\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"759_CR54","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s10067-016-3439-y","volume":"35","author":"D Windschall","year":"2016","unstructured":"Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016;35:2925\u201331. https:\/\/doi.org\/10.1007\/s10067-016-3439-y.","journal-title":"Clin Rheumatol"},{"key":"759_CR55","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763\u20139. https:\/\/doi.org\/10.1056\/NEJM200003163421103.","journal-title":"N Engl J Med"},{"key":"759_CR56","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.39145","volume":"67","author":"G Horneff","year":"2015","unstructured":"Horneff G, Foeldvari I, Minden K, Trauzeddel R, K\u00fcmmerle-Deschner JB, Tenbrock K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67:2240\u20139. https:\/\/doi.org\/10.1002\/art.39145.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13075-019-1916-9","volume":"21","author":"I Foeldvari","year":"2019","unstructured":"Foeldvari I, Constantin T, Vojinovi\u0107 J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019;21:125. https:\/\/doi.org\/10.1186\/s13075-019-1916-9.","journal-title":"Arthritis Res Ther"},{"key":"759_CR58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/rheumatology\/kead183","volume":"63","author":"J Vojinovi\u0107","year":"2024","unstructured":"Vojinovi\u0107 J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, et al. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. Rheumatology (Oxford). 2024;63:140\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kead183.","journal-title":"Rheumatology (Oxford)"},{"key":"759_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","volume":"22","author":"G Armaroli","year":"2020","unstructured":"Armaroli G, Klein A, Ganser G, Ruehlmann MJ, Dressler F, Hospach A, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther. 2020;22:258. https:\/\/doi.org\/10.1186\/s13075-020-02326-5.","journal-title":"Arthritis Res Ther"},{"key":"759_CR60","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","volume":"75","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Niewerth M, Haas J-P, Huppertz H-I, Zink A, Horneff G, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-annrheumdis-2014-206747.","journal-title":"Ann Rheum Dis"},{"key":"759_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/RHU.0000000000002220","volume":"31","author":"N Akay","year":"2025","unstructured":"Akay N, Gul U, Koker O, Erol MA, Yildiz M, Kilic Konte E, et al. Noninfectious uveitis in pediatric rheumatology: long-term follow-up at tertiary centers. J Clin Rheumatol. 2025;31:181\u20137. https:\/\/doi.org\/10.1097\/RHU.0000000000002220.","journal-title":"J Clin Rheumatol"},{"key":"759_CR62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/acr.24839","volume":"74","author":"KB Onel","year":"2021","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Care Res (Hoboken). 2021;74:505\u201320. https:\/\/doi.org\/10.1002\/acr.24839.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR63","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.55563\/clinexprheumatol\/gyrtjo","volume":"40","author":"H Srinivasalu","year":"2022","unstructured":"Srinivasalu H, Oliver M, Stoll ML, Weiss PF, Colbert RA, CARRA Juvenile Spondyloarthritis Workgroup. Survey of current practices in the management of anti-TNF failure in juvenile spondyloarthritis. Clin Exp Rheumatol. 2022;40:1442\u20136. https:\/\/doi.org\/10.55563\/clinexprheumatol\/gyrtjo.","journal-title":"Clin Exp Rheumatol"},{"key":"759_CR64","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SML, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67:1503\u201312. https:\/\/doi.org\/10.1002\/acr.22657.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/ar4072","volume":"14","author":"G Horneff","year":"2012","unstructured":"Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14:R230. https:\/\/doi.org\/10.1186\/ar4072.","journal-title":"Arthritis Res Ther"},{"key":"759_CR66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Tha\u00e7i D, Marcoux D, Weibel L, Philipp S, Ghislain P-D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(17)31189-3.","journal-title":"Lancet"},{"key":"759_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5152\/TurkArchPediatr.2023.23086","volume":"58","author":"\u0130 Tu\u011fal-Tutkun","year":"2023","unstructured":"Tu\u011fal-Tutkun \u0130. An overview of pediatric uveitis. Turk Arch Pediatr. 2023;58:363\u201370. https:\/\/doi.org\/10.5152\/TurkArchPediatr.2023.23086.","journal-title":"Turk Arch Pediatr."},{"key":"759_CR68","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","volume":"23","author":"WA Faubion","year":"2017","unstructured":"Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2017;23:453\u201360. https:\/\/doi.org\/10.1097\/MIB.0000000000001021.","journal-title":"Inflamm Bowel Dis"},{"key":"759_CR69","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00296-023-05352-z","volume":"43","author":"A Zimmer","year":"2023","unstructured":"Zimmer A, Klein A, Kuemmerle-Deschner JB, Dressler F, Onken N, Brueck N, et al. Incident psoriasis under treatment with tumor necrosis factor-\u03b1 inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry. Rheumatol Int. 2023;43:1675\u201384. https:\/\/doi.org\/10.1007\/s00296-023-05352-z.","journal-title":"Rheumatol Int"},{"key":"759_CR70","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-018-4057-7","volume":"37","author":"A Marino","year":"2018","unstructured":"Marino A, Real-Fern\u00e1ndez F, Rovero P, Giani T, Pagnini I, Cimaz R, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37:1407\u201311. https:\/\/doi.org\/10.1007\/s10067-018-4057-7.","journal-title":"Clin Rheumatol"},{"key":"759_CR71","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","volume":"58","author":"MJH Doeleman","year":"2019","unstructured":"Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58:1839\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/kez030.","journal-title":"Rheumatology (Oxford)"},{"key":"759_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-022-02877-9","volume":"24","author":"R Burgos-Vargas","year":"2022","unstructured":"Burgos-Vargas R, Loyola-Sanchez A, Ramiro S, Reding-Bernal A, Alvarez-Hernandez E, van der Heijde D, et al. A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis. Arthritis Res Ther. 2022;24:187. https:\/\/doi.org\/10.1186\/s13075-022-02877-9.","journal-title":"Arthritis Res Ther"},{"key":"759_CR73","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718\u201322. https:\/\/doi.org\/10.1136\/ard.2009.100354.","journal-title":"Ann Rheum Dis"},{"key":"759_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77:21\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210456.","journal-title":"Ann Rheum Dis"},{"key":"759_CR75","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3899\/jrheum.2024-0298","volume":"51","author":"HI Brunner","year":"2024","unstructured":"Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Alexeeva E, Appenzeller S, et al. Intravenous golimumab in children with polyarticular-course juvenile idiopathic arthritis: long-term extension of an open-label phase III study. J Rheumatol. 2024;51:1125\u201334. https:\/\/doi.org\/10.3899\/jrheum.2024-0298.","journal-title":"J Rheumatol"},{"key":"759_CR76","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","volume":"60","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60:4495\u2013507. https:\/\/doi.org\/10.1093\/rheumatology\/keab021.","journal-title":"Rheumatology (Oxford)"},{"key":"759_CR77","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/art.23964","volume":"58","author":"E Keystone","year":"2008","unstructured":"Keystone E, van der Heijde D, Mason D, Landew\u00e9 R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319\u201329. https:\/\/doi.org\/10.1002\/art.23964.","journal-title":"Arthritis Rheum"},{"key":"759_CR78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/ard-2022-222849","volume":"82","author":"HI Brunner","year":"2023","unstructured":"Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82:154\u201360. https:\/\/doi.org\/10.1136\/ard-2022-222849.","journal-title":"Ann Rheum Dis"},{"key":"759_CR79","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/03007995.2019.1620713","volume":"35","author":"B Emond","year":"2019","unstructured":"Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin. 2019;35:1751\u20139. https:\/\/doi.org\/10.1080\/03007995.2019.1620713.","journal-title":"Curr Med Res Opin"},{"key":"759_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00346-7","author":"AV Ramanan","year":"2026","unstructured":"Ramanan AV, Ruperto N, Foeldvari I, Vega-Cornejo G, Keller S, Wang R, et al. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Lancet Rheumatol. 2026. https:\/\/doi.org\/10.1016\/S2665-9913(25)00346-7.","journal-title":"Lancet Rheumatol."},{"key":"759_CR81","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"J Reis","year":"2019","unstructured":"Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33:391\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00361-6.","journal-title":"BioDrugs"},{"key":"759_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, Landew\u00e9 R, Merola JF, Ritchlin CT, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401:25\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02302-9.","journal-title":"Lancet"},{"key":"759_CR83","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/acr.25482","volume":"77","author":"M Shishov","year":"2025","unstructured":"Shishov M, Weiss PF, Levy DM, Chang JC, Angeles-Han ST, Ogbu EA, et al. 25 Years of biologics for the treatment of pediatric rheumatic disease: advances in prognosis and ongoing challenges. Arthritis Care Res. 2025;77:573\u201383. https:\/\/doi.org\/10.1002\/acr.25482.","journal-title":"Arthritis Care Res"},{"key":"759_CR84","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40744-025-00820-3","volume":"13","author":"E Lam","year":"2026","unstructured":"Lam E, Berezny K, Bishop CJ, Lomax KG, Liva SG, Brunner HI, et al. Pharmacokinetics and safety of ustekinumab in patients with juvenile psoriatic arthritis: results of the real-world ustekinumab pediatric opportunistic pharmacokinetics study (U-POPS). Rheumatol Ther. 2026;13:265\u201378. https:\/\/doi.org\/10.1007\/s40744-025-00820-3.","journal-title":"Rheumatol Ther"},{"key":"759_CR85","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","volume":"24","author":"JH Leu","year":"2022","unstructured":"Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, et al. Intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis and subcutaneous ustekinumab in patients with juvenile psoriatic arthritis: extrapolation of data from studies in adults and adjacent pediatric populations. Pediatr Drugs. 2022;24:699\u2013714. https:\/\/doi.org\/10.1007\/s40272-022-00533-y.","journal-title":"Pediatr Drugs"},{"key":"759_CR86","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","volume":"71","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Megna M, Fabbrocini G, Ocampo-Garza SS. Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunol Res. 2023;71:328\u201355. https:\/\/doi.org\/10.1007\/s12026-022-09356-y.","journal-title":"Immunol Res"},{"key":"759_CR87","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/bjd\/ljae502","volume":"192","author":"VH Prajapati","year":"2025","unstructured":"Prajapati VH, Seyger MMB, Wilsmann-Theis D, Szakos E, Kaszuba A, van Hartingsveldt B, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. Br J Dermatol. 2025;192:618\u201328. https:\/\/doi.org\/10.1093\/bjd\/ljae502.","journal-title":"Br J Dermatol"},{"key":"759_CR88","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke W-H, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8.","journal-title":"Lancet"},{"key":"759_CR89","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet"},{"key":"759_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537.","journal-title":"Annu Rev Med"},{"key":"759_CR91","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521\u201346. https:\/\/doi.org\/10.1007\/s40265-017-0701-9.","journal-title":"Drugs"},{"key":"759_CR92","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40272-023-00594-7","volume":"25","author":"NK Bagri","year":"2023","unstructured":"Bagri NK, Chew C, Ramanan AV. Scope of JAK inhibitors in children: recent evidence and way forward. Paediatr Drugs. 2023;25:635\u201347. https:\/\/doi.org\/10.1007\/s40272-023-00594-7.","journal-title":"Paediatr Drugs"},{"key":"759_CR93","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398:1984\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1.","journal-title":"Lancet"},{"key":"759_CR94","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/ard-2023-225094","volume":"83","author":"HI Brunner","year":"2024","unstructured":"Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, et al. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024;83:1561\u201371. https:\/\/doi.org\/10.1136\/ard-2023-225094.","journal-title":"Ann Rheum Dis"},{"key":"759_CR95","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutov\u00e1 \u0160, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402:555\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)00921-2.","journal-title":"Lancet"},{"key":"759_CR96","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","volume":"133","author":"M Chen","year":"2020","unstructured":"Chen M, Dai S-M. A novel treatment for psoriatic arthritis: janus kinase inhibitors. Chin Med J (Engl). 2020;133:959\u201367. https:\/\/doi.org\/10.1097\/CM9.0000000000000711.","journal-title":"Chin Med J (Engl)"},{"key":"759_CR97","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/acr.25465","volume":"77","author":"HI Brunner","year":"2025","unstructured":"Brunner HI, Shmagel A, Horneff G, Foeldvari I, Ant\u00f3n J, Ramanan AV, et al. Pharmacokinetics, efficacy, and safety of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial. Arthritis Care Res (Hoboken). 2025;77:584\u201393. https:\/\/doi.org\/10.1002\/acr.25465.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR98","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-023-03128-1","volume":"25","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Li Y, et al. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther. 2023;25:172. https:\/\/doi.org\/10.1186\/s13075-023-03128-1.","journal-title":"Arthritis Res Ther"},{"key":"759_CR99","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40466","volume":"70","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penad\u00e9s I, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol. 2018;70:1144\u201354. https:\/\/doi.org\/10.1002\/art.40466.","journal-title":"Arthritis Rheumatol"},{"key":"759_CR100","doi-asserted-by":"publisher","first-page":"SI195","DOI":"10.1093\/rheumatology\/keae025","volume":"63","author":"DJ Lovell","year":"2024","unstructured":"Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, et al. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO\/PRCSG registry. Rheumatology (Oxford). 2024;63:SI195-206. https:\/\/doi.org\/10.1093\/rheumatology\/keae025.","journal-title":"Rheumatology (Oxford)"},{"key":"759_CR101","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724.","journal-title":"Ann Rheum Dis"},{"key":"759_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152774","volume":"74","author":"MR Pellico","year":"2025","unstructured":"Pellico MR, Pandolfi M, Amati A, Iannone C, Germinario S, Costi S, et al. The effectiveness and safety of rituximab in juvenile idiopathic arthritis: hints from the ITHACA monocentric registry. Semin Arthritis Rheum. 2025;74:152774. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152774.","journal-title":"Semin Arthritis Rheum"},{"key":"759_CR103","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"I-H Song","year":"2010","unstructured":"Song I-H, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62:1290\u20137. https:\/\/doi.org\/10.1002\/art.27383.","journal-title":"Arthritis Rheum"},{"key":"759_CR104","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1136\/ard-2024-225833","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Coates LC, Gladman DD, Aelion JA, Vasandani J, Pinter A, et al. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Ann Rheum Dis. 2024;83:1480\u20138. https:\/\/doi.org\/10.1136\/ard-2024-225833.","journal-title":"Ann Rheum Dis"},{"key":"759_CR105","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366. https:\/\/doi.org\/10.1002\/art.24516.","journal-title":"Arthritis Rheum"},{"key":"759_CR106","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/rheumatology\/key246","volume":"57","author":"A Zanwar","year":"2018","unstructured":"Zanwar A, Phatak S, Aggarwal A. Prospective validation of the juvenile spondyloarthritis disease activity index in children with enthesitis-related arthritis. Rheumatology (Oxford). 2018;57:2167\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/key246.","journal-title":"Rheumatology (Oxford)"},{"key":"759_CR107","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/RHU.0000000000002001","volume":"29","author":"MC Polat","year":"2023","unstructured":"Polat MC, Ekici Tekin Z, \u00c7elikel E, G\u00fcng\u00f6rer V, Kurt T, Kaplan MM, et al. The juvenile spondyloarthritis disease activity index is a useful tool in enthesitis-related arthritis: real-life data. J Clin Rheumatol. 2023;29:309\u201315. https:\/\/doi.org\/10.1097\/RHU.0000000000002001.","journal-title":"J Clin Rheumatol"},{"key":"759_CR108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3899\/jrheum.2025-0294","volume":"53","author":"PF Weiss","year":"2026","unstructured":"Weiss PF, Ruperto N, Quebe-Fehling E, Shew A, Pricop L, Pieterse CC, et al. Juvenile spondyloarthritis disease activity index validation in enthesitis-related arthritis and juvenile psoriatic arthritis in a prospective clinical trial setting. J Rheumatol. 2026;53:85\u201394. https:\/\/doi.org\/10.3899\/jrheum.2025-0294.","journal-title":"J Rheumatol"},{"key":"759_CR109","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jped.2021.08.002","volume":"98","author":"H Lassoued Ferjani","year":"2022","unstructured":"Lassoued Ferjani H, Maatallah K, Miri S, Triki W, Nessib DB, Kaffel D, et al. Enthesitis-related arthritis: monitoring and specific tools. J Pediatr (Rio J). 2022;98:223\u20139. https:\/\/doi.org\/10.1016\/j.jped.2021.08.002.","journal-title":"J Pediatr (Rio J)"},{"key":"759_CR110","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.220509","volume":"50","author":"H Srinivasalu","year":"2023","unstructured":"Srinivasalu H, Treemarcki EB, Rumsey DG, Weiss PF, Colbert RA, CARRA Spondyloarthritis Workgroup and the CARRA Registry Investigators. Modified juvenile spondyloarthritis disease activity index in the childhood arthritis and rheumatology research alliance (CARRA) registry. J Rheumatol. 2023;50:532\u20137. https:\/\/doi.org\/10.3899\/jrheum.220509.","journal-title":"J Rheumatol"},{"key":"759_CR111","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/BOR.0000000000000948","volume":"35","author":"D Abel","year":"2023","unstructured":"Abel D, Weiss PF. When to stop medication in juvenile idiopathic arthritis. Curr Opin Rheumatol. 2023;35:265\u201372. https:\/\/doi.org\/10.1097\/BOR.0000000000000948.","journal-title":"Curr Opin Rheumatol"},{"key":"759_CR112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12969-019-0363-0","volume":"17","author":"Y-J Shih","year":"2019","unstructured":"Shih Y-J, Yang Y-H, Lin C-Y, Chang C-L, Chiang B-L. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease. Pediatr Rheumatol Online J. 2019;17:58. https:\/\/doi.org\/10.1186\/s12969-019-0363-0.","journal-title":"Pediatr Rheumatol Online J"},{"key":"759_CR113","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol Hoboken, NJ. 2020;72:1945\u201351. https:\/\/doi.org\/10.1002\/art.41390.","journal-title":"Arthritis Rheumatol. Hoboken, N.J."},{"key":"759_CR114","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RML, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015;67:658\u201366. https:\/\/doi.org\/10.1002\/acr.22477.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"759_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-07038-6","volume":"24","author":"PF Weiss","year":"2023","unstructured":"Weiss PF, Sears CE, Brandon TG, Forrest CB, Neu E, Kohlheim M, et al. Biologic abatement and capturing kids\u2019 outcomes and flare frequency in juvenile spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial. Trials. 2023;24:100. https:\/\/doi.org\/10.1186\/s13063-022-07038-6.","journal-title":"Trials"},{"key":"759_CR116","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81:815\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221664.","journal-title":"Ann Rheum Dis"},{"key":"759_CR117","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","volume":"79","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79:595\u2013604. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216980.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00759-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:11:01Z","timestamp":1784290261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00759-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00759-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UG, EKK: investigation, writing, original draft preparation. MY, OK: conceptualization, supervision, writing, reviewing and editing. All authors have read and approved the final version of the manuscript, agreeing to take responsibility for all aspects of the work.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}